GlassScriptPhysician profile
Alain Catalin Mita
NPI 1285602565
$8,479.79
in general payments reported to CMS, 2019-2025
28 companies · $4,832 in 2025
The $4,832 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2022: $168 · 2023: $314 · 2024: $2,236 · 2025: $4,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,170 · Food and Beverage: $1,440 · Travel and Lodging: $1,339 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350 · Education: $83.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,170.00 |
| Food and Beverage | $1,439.67 |
| Travel and Lodging | $1,339.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
| Education | $83.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $2,388.42 | 2025 | Loqtorzi |
| E.R. Squibb & Sons, L.L.C. | $2,137.68 | 2023-2024 | |
| Gilead Sciences, INC. | $1,595.32 | 2023-2025 | Trodelvy |
| Life Technologies Corporation | $495.58 | 2019 | |
| Pfizer INC. | $395.31 | 2019-2023 | |
| Genzyme Corporation | $350.00 | 2025 | |
| Daiichi Sankyo INC. | $272.56 | 2024-2025 | Enhertu |
| Theratechnologies INC. | $120.44 | 2022 | |
| Glaxosmithkline, LLC. | $119.70 | 2025 | Zejula |
| Merck Sharp & Dohme LLC | $116.73 | 2024-2025 | Keytruda, Keytruda Qlex |
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Seagen INC. | $104.15 | 2019 | |
| Amgen INC. | $65.44 | 2025 | |
| Tempus Ai, INC | $45.05 | 2024 | |
| Legend Biotech USA INC. | $40.71 | 2025 | Carvykti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.62 | 2024 | Alunbrig |
| Jazz Pharmaceuticals INC. | $29.39 | 2025 | |
| Genentech USA, INC. | $28.08 | 2025 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $26.67 | 2025 | Libtayo |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alain Mita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.